Insider Cluster (4 insiders) ·Filed May 15, 2026

VCEL

Vericel Corp
NEUTRAL
Impact 2/10
Horizondays Processed4mo ago
Insider cluster: 3 insiders, $0.5M total
Actionable Insight • Neutral

The insider selling is too small to warrant a directional read. Monitor for any larger cluster (>0.5% of market cap) or C-suite open-market buying to gauge management conviction.

DirectionNeutral
Confidencehigh
Horizondays
Final — all horizons settled through T+60d
VCEL ▲ +28.28% at T+60d
NEUTRAL call ✓ call won +28.28% · α vs SPY +23.43% · entry $34.87 → $44.73
Entry anchored
May 15, 2026
via day open
T+1d
-1.09%
call -1.09% · α -0.44%
$34.49
settled 5mo ago
T+5d
+0.29%
call +0.29% · α -1.33%
$34.97
settled 4mo ago
T+20d
+10.30%
call +10.30% · α +8.71%
$38.46
settled 4mo ago
T+60d
+28.28%
call +28.28% · α +23.43%
$44.73
settled 7w ago

Price Chart

Loading chart...

Executive Summary

Vericel Corp insiders sold ~$459K in open-market transactions over the past week, representing a trivial 0.027% of the $1.7B market cap. The sales follow a strong Q1 earnings beat and raised guidance, but the dollar amount is immaterial and likely reflects routine post-earnings profit-taking or option exercise-related selling, not a bearish signal.

Key Financial Metrics

Direction
selling
Total Value
$459.0K
Insiders
4

Key Facts

  • Four insider sales totaling ~$459K: Director McLaughlin ($115K), Director Wotton ($83K), CFO Mara ($203K), PAO Siegal ($58K).
  • Sales represent only 0.027% of Vericel's $1.7B market cap — well below the 0.1% materiality threshold.
  • Occurred 4–8 days after Vericel reported Q1 2026 revenue of $68.4M (+30% YoY, beat consensus) and raised FY2026 guidance to $326-336M.

Financial Impact

Total insider sales of ~$459K, negligible vs. $1.7B market cap.

dilution

Risk Factors

  • Further insider selling at elevated volume could signal waning confidence.
  • Stock may be sensitive to upcoming quarterly results and MACI growth trajectory.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
86% bullish (14 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-VCEL-1778875982331
12 reports for VCEL
Performance horizon
50% Hit rate 2 of 4 directional calls best @ T+60▲ +31.08%May 7, 2026
Filters
Rows
Reports for VCEL — sortable, filterable
TypeNow
Aug 5, 2026
8w ago
Insider Cluster
NEUTRAL ★ 2/10
$45.36 $40.89▼ −9.85%▼ −9.25%$40.15 (−11.49%)
Jul 30, 2026
9w ago
8-K
BULLISH ★ 6/10
$47.61 $41.18▼ −13.51%▼ −17.47%$40.15 (−15.67%)
Jul 16, 2026
11w ago
Press Release
NEUTRAL ★ 2/10
$47.81 $44.54▼ −6.84%▼ −10.46%$40.15 (−16.02%)
Jun 30, 2026
13w ago
Insider Cluster
NEUTRAL ★ 2/10
$45.15 $46.62▲ +3.26%▲ +5.44%$40.15 (−11.07%)
Jun 2, 2026
17w ago
144
NEUTRAL ★ 2/10
$34.45 $45.15▲ +31.06%▲ +32.62%$40.15 (+16.55%)
May 15, 2026
20w ago
Insider Cluster
NEUTRAL ★ 2/10
$34.87 $38.46▲ +10.30%▲ +8.71%$40.15 (+15.14%)
May 7, 2026
21w ago
8-K
BULLISH ★ 7/10
$35.13 $34.74▼ −1.11%▼ −4.25%$40.15 (+14.29%)
May 7, 2026
21w ago
Press Release
BULLISH ★ 8/10
$35.13 $34.74▼ −1.11%▼ −4.25%$40.15 (+14.29%)
Apr 23, 2026
23w ago
Press Release
NEUTRAL ★ 3/10
$34.40 $35.40▲ +2.91%▼ −1.73%$40.15 (+16.72%)
Mar 19, 2026
28w ago
DEFA14A
NEUTRAL ★ 3/10
$32.74 $35.68▲ +8.98%▲ +1.36%$40.15 (+22.63%)
Showing 10 of 12

US Market Status

Market Closed — Opens Mon (65h 2m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access
Report published May 15, 2026